Equities Analysts Issue Forecasts for HIMS FY2025 Earnings

Hims & Hers Health, Inc. (NYSE:HIMS) – Equities research analysts at Seaport Res Ptn raised their FY2025 earnings estimates for shares of Hims & Hers Health in a report issued on Monday, February 24th. Seaport Res Ptn analyst A. Kessler now expects that the company will post earnings per share of $0.64 for the year, up from their prior estimate of $0.51. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.29 per share. Seaport Res Ptn also issued estimates for Hims & Hers Health’s FY2026 earnings at $1.10 EPS.

A number of other equities research analysts have also recently weighed in on the company. BTIG Research initiated coverage on Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target for the company. Needham & Company LLC raised their target price on Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research note on Tuesday. Canaccord Genuity Group upped their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Bank of America increased their price target on shares of Hims & Hers Health from $18.00 to $21.00 and gave the company an “underperform” rating in a research note on Thursday, February 20th. Finally, Morgan Stanley cut Hims & Hers Health from an “overweight” rating to an “equal weight” rating and lifted their target price for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $34.47.

Hims & Hers Health Trading Up 5.0 %

NYSE:HIMS opened at $41.87 on Thursday. The stock has a market capitalization of $9.15 billion, a P/E ratio of 95.15 and a beta of 1.35. Hims & Hers Health has a 1 year low of $11.20 and a 1 year high of $72.98. The firm has a 50 day moving average of $35.89 and a 200-day moving average of $26.36.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. The firm had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Creative Planning grew its stake in shares of Hims & Hers Health by 18.1% during the 3rd quarter. Creative Planning now owns 25,925 shares of the company’s stock worth $478,000 after acquiring an additional 3,979 shares in the last quarter. International Assets Investment Management LLC acquired a new position in Hims & Hers Health during the third quarter worth $6,790,000. Diversify Advisory Services LLC grew its position in Hims & Hers Health by 14.9% in the third quarter. Diversify Advisory Services LLC now owns 51,828 shares of the company’s stock valued at $955,000 after purchasing an additional 6,706 shares in the last quarter. Robeco Institutional Asset Management B.V. acquired a new stake in Hims & Hers Health in the 3rd quarter valued at $604,000. Finally, QRG Capital Management Inc. lifted its position in Hims & Hers Health by 3.9% during the 3rd quarter. QRG Capital Management Inc. now owns 162,029 shares of the company’s stock worth $2,985,000 after buying an additional 6,077 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 17,303 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $48.14, for a total transaction of $832,966.42. Following the completion of the transaction, the insider now owns 193,601 shares in the company, valued at approximately $9,319,952.14. This represents a 8.20 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Soleil Boughton sold 4,152 shares of Hims & Hers Health stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the completion of the sale, the insider now directly owns 157,345 shares in the company, valued at $9,549,268.05. This represents a 2.57 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,097,578 shares of company stock valued at $38,080,320. Company insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.